{"id":"heparin","rwe":[],"_fda":{"id":"505f018d-608d-4dd4-b7b9-640b25b0fc44","set_id":"02fb700d-a28c-4d45-b78d-382dc0d5986c","openfda":{"unii":["ZZ45AB24CA"],"route":["INTRAVENOUS","SUBCUTANEOUS"],"rxcui":["1361226","1361615","1362831","1658637","1658659","1659263"],"spl_id":["505f018d-608d-4dd4-b7b9-640b25b0fc44"],"brand_name":["Heparin Sodium"],"spl_set_id":["02fb700d-a28c-4d45-b78d-382dc0d5986c"],"package_ndc":["71288-402-01","71288-402-02","71288-402-10","71288-402-11","71288-402-30","71288-402-31","71288-449-01","71288-449-02","71288-403-01","71288-403-02","71288-403-10","71288-403-11","71288-450-01","71288-450-02","71288-404-01","71288-404-02","71288-404-04","71288-404-05","71288-451-01","71288-451-02"],"product_ndc":["71288-402","71288-449","71288-403","71288-450","71288-404","71288-451"],"generic_name":["HEPARIN SODIUM"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["HEPARIN SODIUM"],"manufacturer_name":["Meitheal Pharmaceuticals Inc."],"application_number":["ANDA211007"],"is_original_packager":[true]},"version":"12","pregnancy":["8.1 Pregnancy Risk Summary There are no available data on Heparin Sodium Injection use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. In published reports, heparin exposure during pregnancy did not show evidence of an increased risk of adverse maternal or fetal outcomes in humans. No teratogenicity, but early embryo-fetal death was observed in animal reproduction studies with administration of heparin sodium to pregnant rats and rabbits during organogenesis at doses approximately 10 times the maximum recommended human dose (MRHD) of 45,000 units/day [see Data ] . Consider the benefits and risks of Heparin Sodium Injection for the mother and possible risks to the fetus when prescribing Heparin Sodium Injection to a pregnant woman. If available, preservative-free Heparin Sodium Injection is recommended when heparin therapy is needed during pregnancy. There are no known adverse outcomes associated with fetal exposure to the preservative benzyl alcohol through maternal drug administration; however, the preservative benzyl alcohol can cause serious adverse events and death when administered intravenously to neonates and infants [see Warnings and Precautions ( 5.4 )] . The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Human Data The maternal and fetal outcomes associated with uses of heparin via various dosing methods and administration routes during pregnancy have been investigated in numerous studies. These studies generally reported normal deliveries with no maternal or fetal bleeding and no other complications. Animal Data In a published study conducted in rats and rabbits, pregnant animals received heparin intravenously during organogenesis at a dose of 10,000 units/kg/day, approximately 10 times the maximum human daily dose based on body weight. The number of early resorptions increased in both species. There was no evidence of teratogenic effects."],"overdosage":["10 OVERDOSAGE Bleeding is the chief sign of heparin overdosage. Neutralization of Heparin Effect When clinical circumstances (bleeding) require reversal of the heparin effect, protamine sulfate (1% solution) by slow infusion will neutralize heparin sodium. No more than 50 mg should be administered, very slowly , in any 10-minute period. Each mg of protamine sulfate neutralizes approximately 100 USP heparin units. The amount of protamine required decreases over time as heparin is metabolized. Although the metabolism of heparin is complex, it may, for the purpose of choosing a protamine dose, be assumed to have a half-life of about 1/2 hour after intravenous injection. Because fatal reactions often resembling anaphylaxis have been reported with protamine, it should be given only when resuscitation techniques and treatment of anaphylactoid shock are readily available. For additional information consult the labeling of Protamine Sulfate Injection."],"description":["11 DESCRIPTION Heparin is a heterogeneous group of straight-chain anionic mucopolysaccharides, called glycosaminoglycans, possessing anticoagulant properties. It is composed of polymers of alternating derivations of α-D-glucosamido ( N -sulfated O -sulfated or N -acetylated) and O -sulfated uronic acid (α-L-iduronic acid or β-D-glucoronic acid). Structure of heparin sodium (representative subunits): Heparin Sodium Injection, USP is a sterile solution of heparin sodium derived from porcine intestinal mucosa, standardized for anticoagulant activity. It is to be administered by intravenous or deep subcutaneous routes. The potency is determined by a biological assay using a USP reference standard based on units of heparin activity per milligram. Heparin Sodium Injection, USP preserved with Benzyl Alcohol is available in the following concentrations per mL: Heparin Sodium Sodium Chloride Benzyl Alcohol 1,000 USP units 8.6 mg 10.42 mg 5,000 USP units 7 mg 10.42 mg 10,000 USP units 5 mg 10.42 mg pH 5.0-7.5; sodium hydroxide and/or hydrochloric acid added, if needed, for pH adjustment. Structure of Heparin Sodium"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Heparin Sodium Injection preserved with benzyl alcohol is available in the following strengths and package sizes: NDC Heparin Sodium Injection, USP (1,000 USP units per mL) Package Factor 71288- 402 -02 1,000 USP units per mL, Single-Dose Vial* 25 vials per carton 71288- 449 -02 1,000 USP units per mL, Multi-Dose Vial 25 vials per carton 71288- 402 -11 10,000 USP units per 10 mL, Multi-Dose Vial 25 vials per carton 71288- 402 -31 30,000 USP units per 30 mL, Multi-Dose Vial 25 vials per carton NDC Heparin Sodium Injection, USP (5,000 USP units per mL) Package Factor 71288- 403 -02 5,000 USP units per mL, Single-Dose Vial* 25 vials per carton 71288- 450 -02 5,000 USP units per mL, Multi-Dose Vial 25 vials per carton 71288- 403 -11 50,000 USP units per 10 mL, Multi-Dose Vial 25 vials per carton NDC Heparin Sodium Injection, USP (10,000 USP units per mL) Package Factor 71288- 404 -02 10,000 USP units per mL, Single-Dose Vial* 25 vials per carton 71288- 451 -02 10,000 USP units per mL, Multi-Dose Vial 25 vials per carton 71288- 404 -05 40,000 USP units per 4 mL, Multi-Dose Vial 25 vials per carton *Discard unused portion. Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F). [See USP Controlled Room Temperature.] Sterile, Nonpyrogenic. The container closure is not made with natural rubber latex."],"geriatric_use":["8.5 Geriatric Use There are limited adequate and well-controlled studies in patients 65 years and older, however, a higher incidence of bleeding has been reported in patients, particularly women, over 60 years of age [see Warnings and Precautions ( 5.2 )] . Patients over 60 years of age may require lower doses of heparin. Lower doses of heparin may be indicated in these patients [see Clinical Pharmacology ( 12.3 )] ."],"pediatric_use":["8.4 Pediatric Use There are no adequate and well controlled studies on heparin use in pediatric patients. Pediatric dosing recommendations are based on clinical experience [see Dosage and Administration ( 2.5 )] . Carefully examine all Heparin Sodium Injection vials to confirm choice of the correct strength prior to administration of the drug. Pediatric patients, including neonates, have died as a result of medication errors in which Heparin Sodium Injection vials have been confused with “catheter lock flush” vials [see Warnings and Precautions ( 5.1 )] . Benzyl Alcohol Toxicity Use preservative-free Heparin Sodium Injection in neonates and infants. Serious adverse reactions including fatal reactions and the “gasping syndrome” occurred in premature neonates and infants in the neonatal intensive care unit who received drugs containing benzyl alcohol as a preservative. In these cases, benzyl alcohol dosages of 99 to 234 mg/kg/day produced high levels of benzyl alcohol and its metabolites in the blood and urine (blood levels of benzyl alcohol were 0.61 to 1.378 mmol/L). Additional adverse reactions included gradual neurological deterioration, seizures, intracranial hemorrhage, hematologic abnormalities, skin breakdown, hepatic and renal failure, hypotension, bradycardia, and cardiovascular collapse. Preterm, low-birth weight infants may be more likely to develop these reactions because they may be less able to metabolize benzyl alcohol."],"effective_time":"20250926","pharmacodynamics":["12.2 Pharmacodynamics Various times (activated clotting time, activated partial thromboplastin time, prothrombin time, whole blood clotting time) are prolonged by full therapeutic doses of heparin; in most cases, they are not measurably affected by low doses of heparin. The bleeding time is usually unaffected by heparin."],"pharmacokinetics":["12.3 Pharmacokinetics Absorption Heparin is not absorbed through the gastrointestinal tract and therefore administered via parenteral route. Peak plasma concentration and the onset of action are achieved immediately after intravenous administration. Distribution Heparin is highly bound to antithrombin, fibrinogens, globulins, serum proteases and lipoproteins. The volume of distribution is 0.07 L/kg. Elimination Metabolism Heparin does not undergo enzymatic degradation. Excretion Heparin is mainly cleared from the circulation by liver and reticuloendothelial cells mediated uptake into extravascular space. Heparin undergoes biphasic clearance, a) rapid saturable clearance (zero order process due to binding to proteins, endothelial cells and macrophage) and b) slower first order elimination. The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h. Specific Populations Geriatric patients Patients over 60 years of age, following similar doses of heparin, may have higher plasma levels of heparin and longer activated partial thromboplastin times (APTTs) compared with patients under 60 years of age [see Use in Specific Populations ( 8.5 )] ."],"adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Hemorrhage [see Warnings and Precautions ( 5.2 )] Heparin-Induced Thrombocytopenia and Heparin-Induced Thrombocytopenia and Thrombosis [see Warnings and Precautions ( 5.3 )] Risk of Serious Adverse Reactions in Infants Due to Benzyl Alcohol Preservative [ see Warnings and Precautions ( 5.4 ) ] Thrombocytopenia [see Warnings and Precautions ( 5.5 )] Heparin Resistance [see Warnings and Precautions ( 5.7 )] Hypersensitivity [see Warnings and Precautions ( 5.8 )] Hyperkalemia [see Warnings and Precautions ( 5.9 )] Most common adverse reactions are hemorrhage, thrombocytopenia, HIT and HITTS, injection site irritation, general hypersensitivity reactions, and elevations of aminotransferase levels. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Meitheal Pharmaceuticals Inc. at 1-844-824-8426 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Postmarketing Experience The following adverse reactions have been identified during post approval use of Heparin Sodium Injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Hemorrhage is the chief complication that may result from heparin therapy [see Warnings and Precautions ( 5.2 )] . Gastrointestinal or urinary tract bleeding during anticoagulant therapy may indicate the presence of an underlying occult lesion. Bleeding can occur at any site but certain specific hemorrhagic complications may be difficult to detect: Adrenal hemorrhage, with resultant acute adrenal insufficiency, has occurred with heparin therapy, including fatal cases. Ovarian (corpus luteum) hemorrhage developed in a number of women of reproductive age receiving short- or long-term heparin therapy. Retroperitoneal hemorrhage. HIT and HITT, including delayed onset cases [see Warnings and Precautions ( 5.3 )]. Local Irritation – Local irritation, erythema, mild pain, hematoma or ulceration may follow deep subcutaneous (intrafat) injection of heparin sodium. Because these complications are much more common after intramuscular use, the intramuscular route is not recommended. Histamine-like reactions – Such reactions have been observed at the site of injections. Necrosis of the skin has been reported at the site of subcutaneous injection of heparin, occasionally requiring skin grafting [see Warnings and Precautions ( 5.3 )] . Hypersensitivity – Generalized hypersensitivity reactions have been reported, with chills, fever and urticaria as the most usual manifestations, and asthma, rhinitis, lacrimation, headache, nausea and vomiting, and anaphylactoid reactions, including shock, occurring less frequently. Itching and burning, especially on the plantar side of the feet, may occur [see Warnings and Precautions ( 5.8 )] . Elevations of aminotransferases – Significant elevations of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels have occurred in patients who have received heparin. Miscellaneous - Osteoporosis following long-term administration of high doses of heparin, cutaneous necrosis after systemic administration, suppression of aldosterone synthesis, delayed transient alopecia, priapism, and rebound hyperlipemia on discontinuation of heparin sodium have also been reported. Metabolism and Nutrition Disorders – Hyperkalemia."],"contraindications":["4 CONTRAINDICATIONS The use of Heparin Sodium Injection is contraindicated in patients with the following conditions: History of heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis [see Warnings and Precautions ( 5.3 )] ; Known hypersensitivity to heparin or pork products (e.g., anaphylactoid reactions) [see Adverse Reactions ( 6.1 )] ; In whom suitable blood coagulation tests, e.g., the whole blood clotting time, partial thromboplastin time, etc., cannot be performed at appropriate intervals (this contraindication refers to full-dose heparin; there is usually no need to monitor coagulation parameters in patients receiving low-dose heparin); An uncontrolled active bleeding state [see Warnings and Precautions ( 5.2 )] , except when this is due to disseminated intravascular coagulation. Severe thrombocytopenia ( 4 ) When suitable blood coagulation tests, e.g., the whole blood clotting time, partial thromboplastin time, etc., cannot be performed at appropriate intervals ( 4 ) An uncontrolled active bleeding state, except when this is due to disseminated intravascular coagulation ( 4 )"],"description_table":["
Heparin SodiumSodium ChlorideBenzyl Alcohol
1,000 USP units8.6 mg10.42 mg
5,000 USP units7 mg10.42 mg
10,000 USP units5 mg10.42 mg
"],"drug_interactions":["7 DRUG INTERACTIONS Drugs that interfere with platelet aggregation: May induce bleeding ( 7.2 ) 7.1 Oral Anticoagulants Heparin sodium may prolong the one-stage prothrombin time. Therefore, when heparin sodium is given with dicumarol or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn, if a valid prothrombin time is to be obtained. 7.2 Platelet Inhibitors Drugs such as NSAIDS (including salicylic acid, ibuprofen, indomethacin, and celecoxib), dextran, phenylbutazone, thienopyridines, dipyridamole, hydroxychloroquine, glycoprotein IIb/IIIa antagonists (including abciximab, eptifibatide, and tirofiban), and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium. To reduce the risk of bleeding, a reduction in the dose of antiplatelet agent or heparin is recommended. 7.3 Other Interactions Digitalis, tetracyclines, nicotine or antihistamines may partially counteract the anticoagulant action of heparin sodium. Intravenous nitroglycerin administered to heparinized patients may result in a decrease of the partial thromboplastin time with subsequent rebound effect upon discontinuation of nitroglycerin. Careful monitoring of partial thromboplastin time and adjustment of heparin dosage are recommended during coadministration of heparin and intravenous nitroglycerin. Antithrombin III (human) – The anticoagulant effect of heparin is enhanced by concurrent treatment with antithrombin III (human) in patients with hereditary antithrombin III deficiency. To reduce the risk of bleeding, a reduced dosage of heparin is recommended during treatment with antithrombin III (human)."],"how_supplied_table":["
NDCHeparin Sodium Injection, USP (1,000 USP units per mL)Package Factor
71288-402-02 1,000 USP units per mL, Single-Dose Vial* 25 vials per carton
71288-449-02 1,000 USP units per mL, Multi-Dose Vial 25 vials per carton
71288-402-11 10,000 USP units per 10 mL, Multi-Dose Vial 25 vials per carton
71288-402-31 30,000 USP units per 30 mL, Multi-Dose Vial 25 vials per carton
NDCHeparin Sodium Injection, USP (5,000 USP units per mL)Package Factor
71288-403-02 5,000 USP units per mL, Single-Dose Vial* 25 vials per carton
71288-450-02 5,000 USP units per mL, Multi-Dose Vial 25 vials per carton
71288-403-11 50,000 USP units per 10 mL, Multi-Dose Vial 25 vials per carton
NDCHeparin Sodium Injection, USP (10,000 USP units per mL)Package Factor
71288-404-02 10,000 USP units per mL, Single-Dose Vial* 25 vials per carton
71288-451-02 10,000 USP units per mL, Multi-Dose Vial 25 vials per carton
71288-404-05 40,000 USP units per 4 mL, Multi-Dose Vial 25 vials per carton
"],"mechanism_of_action":["12.1 Mechanism of Action Heparin interacts with the naturally occurring plasma protein, Antithrombin III, to induce a conformational change, which markedly enhances the serine protease activity of Antithrombin III, thereby inhibiting the activated coagulation factors involved in the clotting sequence, particularly Xa and IIa. Small amounts of heparin inhibit Factor Xa, and larger amounts inhibit thrombin (Factor IIa). Heparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor. Heparin does not have fibrinolytic activity; therefore, it will not lyse existing clots."],"recent_major_changes":["Warnings and Precautions, Hyperkalemia (5.9) 06/2024"],"storage_and_handling":["Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F). [See USP Controlled Room Temperature.] Sterile, Nonpyrogenic. The container closure is not made with natural rubber latex."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Heparin interacts with the naturally occurring plasma protein, Antithrombin III, to induce a conformational change, which markedly enhances the serine protease activity of Antithrombin III, thereby inhibiting the activated coagulation factors involved in the clotting sequence, particularly Xa and IIa. Small amounts of heparin inhibit Factor Xa, and larger amounts inhibit thrombin (Factor IIa). Heparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor. Heparin does not have fibrinolytic activity; therefore, it will not lyse existing clots. 12.2 Pharmacodynamics Various times (activated clotting time, activated partial thromboplastin time, prothrombin time, whole blood clotting time) are prolonged by full therapeutic doses of heparin; in most cases, they are not measurably affected by low doses of heparin. The bleeding time is usually unaffected by heparin. 12.3 Pharmacokinetics Absorption Heparin is not absorbed through the gastrointestinal tract and therefore administered via parenteral route. Peak plasma concentration and the onset of action are achieved immediately after intravenous administration. Distribution Heparin is highly bound to antithrombin, fibrinogens, globulins, serum proteases and lipoproteins. The volume of distribution is 0.07 L/kg. Elimination Metabolism Heparin does not undergo enzymatic degradation. Excretion Heparin is mainly cleared from the circulation by liver and reticuloendothelial cells mediated uptake into extravascular space. Heparin undergoes biphasic clearance, a) rapid saturable clearance (zero order process due to binding to proteins, endothelial cells and macrophage) and b) slower first order elimination. The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h. Specific Populations Geriatric patients Patients over 60 years of age, following similar doses of heparin, may have higher plasma levels of heparin and longer activated partial thromboplastin times (APTTs) compared with patients under 60 years of age [see Use in Specific Populations ( 8.5 )] ."],"indications_and_usage":["1 INDICATIONS AND USAGE Heparin Sodium Injection is indicated for: Prophylaxis and treatment of venous thrombosis and pulmonary embolism; Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease; Atrial fibrillation with embolization; Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); Prevention of clotting in arterial and cardiac surgery; Prophylaxis and treatment of peripheral arterial embolism. Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures. HEPARIN SODIUM INJECTION is an anticoagulant indicated for ( 1 ) Prophylaxis and treatment of venous thrombosis and pulmonary embolism Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease Atrial fibrillation with embolization Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation) Prevention of clotting in arterial and cardiac surgery Prophylaxis and treatment of peripheral arterial embolism Use as an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Fatal Medication Errors: Confirm choice of correct strength prior to administration ( 5.1 ) Hemorrhage: Fatal cases have occurred. Use caution in conditions with increased risk of hemorrhage ( 5.2 ) HIT and HITTS: Monitor for signs and symptoms and discontinue if indicative of HIT and HITTS ( 5.3 ) Benzyl Alcohol Toxicity: Do not use benzyl alcohol-preserved drugs in neonates and infants. ( 5.4 ) Monitoring: Blood coagulation tests guide therapy for full-dose heparin. Monitor platelet count and hematocrit in all patients receiving heparin ( 5.5 , 5.6 ) Hyperkalemia: Measure blood potassium in patients at risk of hyperkalemia before starting heparin therapy and periodically in all patients ( 5.9 ) 5.1 Fatal Medication Errors Do not use Heparin Sodium Injection as a “catheter lock flush” product. Heparin Sodium Injection is supplied in vials containing various strengths of heparin, including vials that contain a highly concentrated solution of 10,000 units in 1 mL. Fatal hemorrhages have occurred in pediatric patients due to medication errors in which 1 mL Heparin Sodium Injection vials were confused with 1 mL “catheter lock flush” vials. Carefully examine all Heparin Sodium Injection vials to confirm the correct vial choice prior to administration of the drug. 5.2 Hemorrhage Avoid using heparin in the presence of major bleeding, except when the benefits of heparin therapy outweigh the potential risks. Hemorrhage can occur at virtually any site in patients receiving heparin. Fatal hemorrhages have occurred. Adrenal hemorrhage (with resultant acute adrenal insufficiency), ovarian hemorrhage, and retroperitoneal hemorrhage have occurred during anticoagulant therapy with heparin [see Adverse Reactions ( 6.1 )] . A higher incidence of bleeding has been reported in patients, particularly women, over 60 years of age [see Clinical Pharmacology ( 12.3 )] . An unexplained fall in hematocrit, fall in blood pressure or any other unexplained symptom should lead to serious consideration of a hemorrhagic event. Use heparin sodium with caution in disease states in which there is increased risk of hemorrhage, including: Cardiovascular - Subacute bacterial endocarditis, severe hypertension. Surgical - During and immediately following (a) spinal tap or spinal anesthesia or (b) major surgery, especially involving the brain, spinal cord, or eye. Hematologic - Conditions associated with increased bleeding tendencies, such as hemophilia, thrombocytopenia and some vascular purpuras. Patients with hereditary antithrombin III deficiency receiving concurrent antithrombin III therapy - The anticoagulant effect of heparin is enhanced by concurrent treatment with antithrombin III (human) in patients with hereditary antithrombin III deficiency. To reduce the risk of bleeding, reduce the heparin dose during concomitant treatment with antithrombin III (human). Gastrointestinal - Ulcerative lesions and continuous tube drainage of the stomach or small intestine. Other - Menstruation, liver disease with impaired hemostasis. 5.3 Heparin-Induced Thrombocytopenia and Heparin-Induced Thrombocytopenia and Thrombosis Heparin-induced thrombocytopenia (HIT) is a serious antibody-mediated reaction. HIT occurs in patients treated with heparin and is due to the development of antibodies to a platelet Factor 4-heparin complex that induce in vivo platelet aggregation. HIT may progress to the development of venous and arterial thromboses, a condition referred to as heparin-induced thrombocytopenia with thrombosis (HITT). Thrombotic events may also be the initial presentation for HITT. These serious thromboembolic events include deep vein thrombosis, pulmonary embolism, cerebral vein thrombosis, limb ischemia, stroke, myocardial infarction, mesenteric thrombosis, renal arterial thrombosis, skin necrosis, gangrene of the extremities that may lead to amputation, and possibly death. If the platelet count falls below 100,000/mm 3 or if recurrent thrombosis develops, promptly discontinue heparin, evaluate for HIT and HITT, and, if necessary, administer an alternative anticoagulant. HIT or HITT can occur up to several weeks after the discontinuation of heparin therapy. Patients presenting with thrombocytopenia or thrombosis after discontinuation of heparin sodium should be evaluated for HIT or HITT. 5.4 Risk of Serious Adverse Reactions in Infants Due to Benzyl Alcohol Preservative Serious and fatal adverse reactions including “gasping syndrome” can occur in neonates and infants treated with benzyl alcohol-preserved drugs, including Heparin Sodium Injection vials. The “gasping syndrome” is characterized by central nervous system depression, metabolic acidosis, and gasping respirations. When prescribing Heparin Sodium Injection vials in infants consider the combined daily metabolic load of benzyl alcohol from all sources including Heparin Sodium Injection vials (contains 10.42 mg of benzyl alcohol per mL) and other drugs containing benzyl alcohol. The minimum amount of benzyl alcohol at which toxicity may occur is not known [see Use in Specific Populations ( 8.4 )] . 5.5 Thrombocytopenia Thrombocytopenia in patients receiving heparin has been reported at frequencies up to 30%. It can occur 2 to 20 days (average 5 to 9) following the onset of heparin therapy. Obtain platelet counts before and periodically during heparin therapy. Monitor thrombocytopenia of any degree closely. If the count falls below 100,000/mm 3 or if recurrent thrombosis develops, promptly discontinue heparin, evaluate for HIT and HITT, and, if necessary, administer an alternative anticoagulant [see Warnings and Precautions ( 5.3 )]. 5.6 Coagulation Testing and Monitoring When using a full dose heparin regimen, adjust the heparin dose based on frequent blood coagulation tests. If the coagulation test is unduly prolonged or if hemorrhage occurs, discontinue heparin promptly [see Overdosage (10)]. Periodic platelet counts and hematocrits are recommended during the entire course of heparin therapy, regardless of the route of administration [see Dosage and Administration ( 2.3 )] . 5.7 Heparin Resistance Resistance to heparin is frequently encountered in fever, thrombosis, thrombophlebitis, infections with thrombosing tendencies, myocardial infarction, cancer, in postsurgical patients, and patients with antithrombin III deficiency. Close monitoring of coagulation tests is recommended in these cases. Adjustment of heparin doses based on anti-Factor Xa levels may be warranted. 5.8 Hypersensitivity Patients with documented hypersensitivity to heparin should be given the drug only in clearly life-threatening situations. Because Heparin Sodium Injection is derived from animal tissue, it should be used with caution in patients with a history of allergy. 5.9 Hyperkalemia Heparin can suppress adrenal secretion of aldosterone leading to hyperkalemia, particularly in patients with diabetes mellitus, chronic renal failure, pre-existing metabolic acidosis, a raised plasma potassium, or taking potassium sparing drugs. The risk of hyperkalemia appears to increase with duration of therapy but is usually reversible upon discontinuation of heparin. Measure blood potassium in patients at risk of hyperkalemia before starting heparin therapy and periodically in all patients treated for more than 5 days or earlier as deemed fit by the clinician."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term studies in animals have been performed to evaluate carcinogenic potential of heparin. Also, no reproduction studies in animals have been performed concerning mutagenesis or impairment of fertility."],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Hemorrhage Inform patients that it may take them longer than usual to stop bleeding, that they may bruise and/or bleed more easily when they are treated with heparin, and that they should report any unusual bleeding or bruising to their physician. Hemorrhage can occur at virtually any site in patients receiving heparin. Fatal hemorrhages have occurred [see Warnings and Precautions ( 5.2 )] . Prior to Surgery Advise patients to inform physicians and dentists that they are receiving heparin before any surgery is scheduled [see Warnings and Precautions ( 5.2 )] . Heparin-Induced Thrombocytopenia Inform patients of the risk of heparin-induced thrombocytopenia (HIT). HIT may progress to the development of venous and arterial thromboses, a condition known as heparin-induced thrombocytopenia and thrombosis (HITT). HIT and HITT can occur up to several weeks after the discontinuation of heparin therapy [see Warnings and Precautions ( 5.3 )] . Hypersensitivity Inform patients that generalized hypersensitivity reactions have been reported. Necrosis of the skin has been reported at the site of subcutaneous injection of heparin [see Warnings and Precautions ( 5.8 ), Adverse Reactions ( 6.1 )] . Other Medications Because of the risk of hemorrhage, advise patients to inform their physicians and dentists of all medications they are taking, including non-prescription medications, and before starting any new medication [see Drug Interactions ( 7.1 )] . meitheal ® Mfd. for Meitheal Pharmaceuticals Chicago, IL 60631 (USA) ©2025 Meitheal Pharmaceuticals Inc. Mfd. by Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. Nanjing, China 210061 Revised: January 2025 8A6NAU9-03"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Recommended Adult Dosages: Therapeutic Anticoagulant Effect with Full-Dose Heparin † ( 2.4 ) † Based on 150 lb (68 kg) patient. Adjust dose based on laboratory monitoring. Deep Subcutaneous (Intrafat) Injection Use a different site for each injection Initial Dose 5,000 units by intravenous injection, followed by 10,000 to 20,000 units of a concentrated solution, subcutaneously Every 8 hours or Every 12 hours 8,000 to 10,000 units of a concentrated solution 15,000 to 20,000 units of a concentrated solution Intermittent Intravenous Injection Initial dose 10,000 units, either undiluted or in 50 to 100 mL of 0.9% Sodium Chloride Injection, USP Every 4 to 6 hours 5,000 to 10,000 units, either undiluted or in 50 to 100 mL of 0.9% Sodium Chloride Injection, USP Intravenous Infusion Initial dose 5,000 units by intravenous injection Continuous 20,000 to 40,000 units/24 hours in 1000 mL of 0.9% Sodium Chloride Injection, USP (or in any compatible solution) for infusion 2.1 Preparation for Administration Confirm the choice of the correct Heparin Sodium Injection vial to ensure that the 1 mL vial is not confused with a “catheter lock flush” vial or other 1 mL vial of incorrect strength [see Warnings and Precautions ( 5.1 )]. Confirm the selection of the correct formulation and strength prior to administration of the drug. To lessen this risk, the 1 mL vial includes a red cautionary statement. Read the cautionary statement and confirm that you have selected the correct medication and strength. When heparin is added to an infusion solution for continuous intravenous administration, invert the container repeatedly to ensure adequate mixing and prevent pooling of the heparin in the solution. Inspect parenteral drug products visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Use only if solution is clear and the seal is intact. Do not use if solution is discolored or contains a precipitate. Administer Heparin Sodium Injection by intermittent intravenous injection, intravenous infusion, or deep subcutaneous (intrafat, i.e., above the iliac crest or abdominal fat layer) injection. Do not administer Heparin Sodium Injection by intramuscular injection because of the risk of hematoma at the injection site [see Adverse Reactions ( 6 )] . 2.3 Laboratory Monitoring for Efficacy and Safety Adjust the dosage of Heparin Sodium Injection according to the patient's coagulation test results. Dosage is considered adequate when the activated partial thromboplastin time (aPTT) is 1.5 to 2 times normal or when the whole blood clotting time is elevated approximately 2.5 to 3 times the control value. When initiating treatment with Heparin Sodium Injection by continuous intravenous infusion, determine the coagulation status (aPTT, INR, platelet count) at baseline and continue to follow aPTT approximately every 4 hours and then at appropriate intervals thereafter. When the drug is administered intermittently by intravenous injection, perform coagulation tests before each injection during the initiation of treatment and at appropriate intervals thereafter. After deep subcutaneous (intrafat) injections, tests for adequacy of dosage are best performed on samples drawn 4 to 6 hours after the injection. Periodic platelet counts and hematocrits are recommended during the entire course of heparin therapy, regardless of the route of administration. 2.4 Therapeutic Anticoagulant Effect with Full-Dose Heparin The dosing recommendations in Table 1 are based on clinical experience. Although dosages must be adjusted for the individual patient according to the results of suitable laboratory tests, the following dosage schedules may be used as guidelines: Table 1: Recommended Adult Full-Dose Heparin Regimens for Therapeutic Anticoagulant Effect METHOD OF ADMINISTRATION FREQUENCY RECOMMENDED DOSE [based on 150 lb (68 kg) patient] Deep Subcutaneous (Intrafat) Injection Initial dose 5,000 units by intravenous injection, followed by 10,000 to 20,000 units of a concentrated solution, subcutaneously A different site should be used for each injection to prevent the development of massive hematoma Every 8 hours or 8,000 to 10,000 units of a concentrated solution Every 12 hours 15,000 to 20,000 units of a concentrated solution Intermittent Intravenous Injection Initial dose 10,000 units, either undiluted or in 50 to 100 mL of 0.9% Sodium Chloride Injection, USP Every 4 to 6 hours 5,000 to 10,000 units, either undiluted or in 50 to 100 mL of 0.9% Sodium Chloride Injection, USP Intravenous Infusion Initial dose Continuous 5,000 units by intravenous injection 20,000 to 40,000 units/24 hours in 1000 mL of 0.9% Sodium Chloride Injection, USP (or in any compatible solution) for infusion 2.5 Pediatric Use Do not use benzyl alcohol-preserved drugs in neonates and infants. Use preservative-free Heparin Sodium Injection in neonates and infants [see Warnings and Precautions ( 5.4 )] . There are no adequate and well controlled studies on heparin use in pediatric patients. Pediatric dosing recommendations are based on clinical experience. In general, the following dosage schedule may be used as a guideline in pediatric patients: Initial Dose 75 to 100 units/kg (Intravenous bolus over 10 minutes) Maintenance Dose Infants: 25 to 30 units/kg/hour; Infants < 2 months have the highest requirements (average 28 units/kg/hour) Children > 1 year of age: 18 to 20 units/kg/hour; Older children may require less heparin, similar to weight-adjusted adult dosage Monitoring Adjust heparin to maintain APTT of 60 to 85 seconds, assuming this reflects an anti-Factor Xa level of 0.35 to 0.70 2.6 Cardiovascular Surgery Patients undergoing total body perfusion for open-heart surgery should receive an initial dose of not less than 150 units of heparin sodium per kilogram of body weight. Frequently, a dose of 300 units per kilogram is used for procedures estimated to last less than 60 minutes, or 400 units per kilogram for those estimated to last longer than 60 minutes. 2.7 Low-Dose Prophylaxis of Postoperative Thromboembolism The most widely used dosage has been 5,000 units 2 hours before surgery and 5,000 units every 8 to 12 hours thereafter for 7 days or until the patient is fully ambulatory, whichever is longer. Administer the heparin by deep subcutaneous (intrafat, i.e., above the iliac crest or abdominal fat layer, arm, or thigh) injection with a fine (25- to 26-gauge) needle to minimize tissue trauma. 2.8 Blood Transfusion Add 450 USP units to 600 USP units of heparin sodium per 100 mL of whole blood to prevent coagulation. Usually, 7,500 USP units of heparin sodium are added to 100 mL of 0.9% Sodium Chloride Injection, USP (or 75,000 USP units per 1000 mL of 0.9% Sodium Chloride Injection, USP) and mixed; from this sterile solution, 6 mL to 8 mL are added per 100 mL of whole blood. 2.9 Converting to Warfarin To ensure continuous anticoagulation when converting from Heparin Sodium Injection to warfarin, continue full heparin therapy for several days until the INR (prothrombin time) has reached a stable therapeutic range. Heparin therapy may then be discontinued without tapering [see Drug Interactions ( 7.1 )] . 2.10 Converting to Oral Anticoagulants other than Warfarin For patients currently receiving intravenous heparin, stop intravenous infusion of heparin sodium immediately after administering the first dose of oral anticoagulant; or for intermittent intravenous administration of heparin sodium, start oral anticoagulant 0 to 2 hours before the time that the next dose of heparin was to have been administered. 2.11 Extracorporeal Dialysis Follow equipment manufacturers' operating directions carefully. A dose of 25 units/kg to 30 units/kg followed by an infusion rate of 1,500 units/hour to 2,000 units/hour is suggested based on pharmacodynamic data if specific manufacturers' recommendations are not available."],"spl_product_data_elements":["Heparin Sodium Heparin Sodium heparin sodium heparin benzyl alcohol hydrochloric acid sodium hydroxide water nitrogen Heparin Sodium Heparin Sodium heparin sodium heparin benzyl alcohol hydrochloric acid sodium hydroxide water nitrogen Heparin Sodium Heparin Sodium heparin sodium heparin benzyl alcohol hydrochloric acid sodium hydroxide water nitrogen Heparin Sodium Heparin Sodium heparin sodium heparin benzyl alcohol hydrochloric acid sodium hydroxide water nitrogen Heparin Sodium Heparin Sodium heparin sodium heparin benzyl alcohol hydrochloric acid sodium hydroxide water nitrogen Heparin Sodium Heparin Sodium heparin sodium heparin benzyl alcohol hydrochloric acid sodium hydroxide water nitrogen"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Heparin Sodium Injection, USP preserved with benzyl alcohol is available as follows: 1,000 USP units per mL single-dose vials 5,000 USP units per mL single-dose vials 10,000 USP units per mL single-dose vials 1,000 USP units per mL multiple-dose vials 5,000 USP units per mL multiple-dose vials 10,000 USP units per mL multiple-dose vials 10,000 USP units per 10 mL (1,000 USP units per mL) multiple-dose vials 30,000 USP units per 30 mL (1,000 USP units per mL) multiple-dose vials 50,000 USP units per 10 mL (5,000 USP units per mL) multiple-dose vials 40,000 USP units per 4 mL (10,000 USP units per mL) multiple-dose vials Injection (preserved with Benzyl Alcohol) ( 3 ) Single-dose Vials 1,000 USP units per mL 5,000 USP units per mL 10,000 USP units per mL Multiple-dose Vials 1,000 USP units per mL 5,000 USP units per mL 10,000 USP units per mL 10,000 USP units per 10 mL (1,000 USP units per mL) 30,000 USP units per 30 mL (1,000 USP units per mL) 50,000 USP units per 10 mL (5,000 USP units per mL) 40,000 USP units per 4 mL (10,000 USP units per mL)"],"recent_major_changes_table":["
Warnings and Precautions, Hyperkalemia (5.9) 06/2024
"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Pregnancy: Preservative-free formulation recommended. Limited human data in pregnant women. ( 8.1 ) Lactation: Advise females not to breastfeed. ( 8.2 ) Pediatric Use: Use preservative-free formulation in neonates and infants. ( 8.4 ) Geriatric Use: A higher incidence of bleeding reported in patients, particularly women, over 60 years of age. ( 8.5 ) 8.1 Pregnancy Risk Summary There are no available data on Heparin Sodium Injection use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. In published reports, heparin exposure during pregnancy did not show evidence of an increased risk of adverse maternal or fetal outcomes in humans. No teratogenicity, but early embryo-fetal death was observed in animal reproduction studies with administration of heparin sodium to pregnant rats and rabbits during organogenesis at doses approximately 10 times the maximum recommended human dose (MRHD) of 45,000 units/day [see Data ] . Consider the benefits and risks of Heparin Sodium Injection for the mother and possible risks to the fetus when prescribing Heparin Sodium Injection to a pregnant woman. If available, preservative-free Heparin Sodium Injection is recommended when heparin therapy is needed during pregnancy. There are no known adverse outcomes associated with fetal exposure to the preservative benzyl alcohol through maternal drug administration; however, the preservative benzyl alcohol can cause serious adverse events and death when administered intravenously to neonates and infants [see Warnings and Precautions ( 5.4 )] . The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Human Data The maternal and fetal outcomes associated with uses of heparin via various dosing methods and administration routes during pregnancy have been investigated in numerous studies. These studies generally reported normal deliveries with no maternal or fetal bleeding and no other complications. Animal Data In a published study conducted in rats and rabbits, pregnant animals received heparin intravenously during organogenesis at a dose of 10,000 units/kg/day, approximately 10 times the maximum human daily dose based on body weight. The number of early resorptions increased in both species. There was no evidence of teratogenic effects. 8.2 Lactation Risk Summary If available, preservative-free Heparin Sodium Injection is recommended when heparin therapy is needed during lactation. Benzyl alcohol present in maternal serum is likely to cross into human milk and may be orally absorbed by a nursing infant. There is no information regarding the presence of Heparin Sodium Injection in human milk, the effects on the breastfed infant, or the effects on milk production. Due to its large molecular weight, heparin is not likely to be excreted in human milk, and any heparin in milk would not be orally absorbed by a nursing infant. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Heparin Sodium Injection and any potential adverse effects on the breastfed infant from Heparin Sodium Injection or from the underlying maternal condition [see Use in Specific Populations ( 8.4 )] . 8.4 Pediatric Use There are no adequate and well controlled studies on heparin use in pediatric patients. Pediatric dosing recommendations are based on clinical experience [see Dosage and Administration ( 2.5 )] . Carefully examine all Heparin Sodium Injection vials to confirm choice of the correct strength prior to administration of the drug. Pediatric patients, including neonates, have died as a result of medication errors in which Heparin Sodium Injection vials have been confused with “catheter lock flush” vials [see Warnings and Precautions ( 5.1 )] . Benzyl Alcohol Toxicity Use preservative-free Heparin Sodium Injection in neonates and infants. Serious adverse reactions including fatal reactions and the “gasping syndrome” occurred in premature neonates and infants in the neonatal intensive care unit who received drugs containing benzyl alcohol as a preservative. In these cases, benzyl alcohol dosages of 99 to 234 mg/kg/day produced high levels of benzyl alcohol and its metabolites in the blood and urine (blood levels of benzyl alcohol were 0.61 to 1.378 mmol/L). Additional adverse reactions included gradual neurological deterioration, seizures, intracranial hemorrhage, hematologic abnormalities, skin breakdown, hepatic and renal failure, hypotension, bradycardia, and cardiovascular collapse. Preterm, low-birth weight infants may be more likely to develop these reactions because they may be less able to metabolize benzyl alcohol. 8.5 Geriatric Use There are limited adequate and well-controlled studies in patients 65 years and older, however, a higher incidence of bleeding has been reported in patients, particularly women, over 60 years of age [see Warnings and Precautions ( 5.2 )] . Patients over 60 years of age may require lower doses of heparin. Lower doses of heparin may be indicated in these patients [see Clinical Pharmacology ( 12.3 )] ."],"dosage_and_administration_table":["
† Based on 150 lb (68 kg) patient. Adjust dose based on laboratory monitoring.
Deep Subcutaneous (Intrafat) Injection Use a different site for each injection Initial Dose5,000 units by intravenous injection, followed by 10,000 to 20,000 units of a concentrated solution, subcutaneously
Every 8 hours or Every 12 hours8,000 to 10,000 units of a concentrated solution 15,000 to 20,000 units of a concentrated solution
Intermittent Intravenous InjectionInitial dose10,000 units, either undiluted or in 50 to 100 mL of 0.9% Sodium Chloride Injection, USP
Every 4 to 6 hours5,000 to 10,000 units, either undiluted or in 50 to 100 mL of 0.9% Sodium Chloride Injection, USP
Intravenous InfusionInitial dose5,000 units by intravenous injection
Continuous20,000 to 40,000 units/24 hours in 1000 mL of 0.9% Sodium Chloride Injection, USP (or in any compatible solution) for infusion
","
Table 1: Recommended Adult Full-Dose Heparin Regimens for Therapeutic Anticoagulant Effect
METHOD OF ADMINISTRATIONFREQUENCYRECOMMENDED DOSE [based on 150 lb (68 kg) patient]
Deep Subcutaneous (Intrafat) InjectionInitial dose5,000 units by intravenous injection, followed by 10,000 to 20,000 units of a concentrated solution, subcutaneously
A different site should be used for each injection to prevent the development of massive hematomaEvery 8 hours or8,000 to 10,000 units of a concentrated solution
Every 12 hours15,000 to 20,000 units of a concentrated solution
Intermittent Intravenous InjectionInitial dose10,000 units, either undiluted or in 50 to 100 mL of 0.9% Sodium Chloride Injection, USP
Every 4 to 6 hours5,000 to 10,000 units, either undiluted or in 50 to 100 mL of 0.9% Sodium Chloride Injection, USP
Intravenous InfusionInitial dose Continuous5,000 units by intravenous injection 20,000 to 40,000 units/24 hours in 1000 mL of 0.9% Sodium Chloride Injection, USP (or in any compatible solution) for infusion
","
Initial Dose75 to 100 units/kg (Intravenous bolus over 10 minutes)
Maintenance DoseInfants: 25 to 30 units/kg/hour; Infants < 2 months have the highest requirements (average 28 units/kg/hour) Children > 1 year of age: 18 to 20 units/kg/hour; Older children may require less heparin, similar to weight-adjusted adult dosage
MonitoringAdjust heparin to maintain APTT of 60 to 85 seconds, assuming this reflects an anti-Factor Xa level of 0.35 to 0.70
"],"package_label_principal_display_panel":["Principal Display Panel – Heparin Sodium Injection, USP 1,000 USP units per mL Vial Label NDC 71288- 402 -01 Rx Only Heparin Sodium Injection, USP 1,000 USP units per mL NOT for Lock Flush For Intravenous or Subcutaneous Use 1 mL Single-Dose Vial Principal Display Panel – Heparin Sodium Injection, USP 1,000 USP units per mL Vial Label","Principal Display Panel – Heparin Sodium Injection, USP 1,000 USP units per mL Carton NDC 71288- 402 -02 25 x 1 mL Single-Dose Vials Discard unused portion Rx Only Heparin Sodium Injection, USP 1,000 USP units per mL NOT for Lock Flush For Intravenous or Subcutaneous Use From Porcine Intestinal Mucosa Principal Display Panel – Heparin Sodium Injection, USP 1,000 USP units per mL Carton","Principal Display Panel – Heparin Sodium Injection, USP 10,000 USP units per 10 mL Vial Label NDC 71288- 402 -10 Rx Only Heparin Sodium Injection, USP 10,000 USP units per 10 mL (1,000 USP units per mL) NOT for Lock Flush For Intravenous or Subcutaneous Use 10 mL Multi-Dose Vial Principal Display Panel – Heparin Sodium Injection, USP 10,000 USP units per 10 mL Vial Label","Principal Display Panel – Heparin Sodium Injection, USP 10,000 USP units per 10 mL Carton NDC 71288- 402 -11 25 x 10 mL Multi-Dose Vials Rx Only Heparin Sodium Injection, USP 10,000 USP units per 10 mL (1,000 USP units per mL) NOT for Lock Flush For Intravenous or Subcutaneous Use From Porcine Intestinal Mucosa Principal Display Panel – Heparin Sodium Injection, USP 10,000 USP units per 10 mL Carton","Principal Display Panel – Heparin Sodium Injection, USP 30,000 USP units per 30 mL Vial Label NDC 71288- 402 -30 Rx only Heparin Sodium Injection, USP 30,000 USP units per 30 mL (1,000 USP units per mL) NOT for Lock Flush For Intravenous or Subcutaneous Use 30 mL Multi-Dose Vial From Porcine Intestinal Mucosa Principal Display Panel – Heparin Sodium Injection, USP 30,000 USP units per 30 mL Vial Label","Principal Display Panel – Heparin Sodium Injection, USP 30,000 USP units per 30 mL Carton NDC 71288- 402 -31 25 x 30 mL Multi-Dose Vials Rx Only Heparin Sodium Injection, USP 30,000 USP units per 30 mL (1,000 USP units per mL) NOT for Lock Flush For Intravenous or Subcutaneous Use From Porcine Intestinal Mucosa Principal Display Panel – Heparin Sodium Injection, USP 30,000 USP units per 30 mL Carton","Principal Display Panel – Heparin Sodium Injection, USP 5,000 USP units per mL Vial Label NDC 71288- 403 -01 Rx only Heparin Sodium Injection, USP 5,000 USP units per mL NOT for Lock Flush For Intravenous or Subcutaneous Use 1 mL Single-Dose Vial Principal Display Panel – Heparin Sodium Injection, USP 5,000 USP units per mL Vial Label","Principal Display Panel – Heparin Sodium Injection, USP 5,000 USP units per mL Carton NDC 71288- 403 -02 25 x 1 mL Single-Dose Vials Discard unused portion Rx Only Heparin Sodium Injection, USP 5,000 USP units per mL NOT for Lock Flush For Intravenous or Subcutaneous Use From Porcine Intestinal Mucosa Principal Display Panel – Heparin Sodium Injection, USP 5,000 USP units per mL Carton","Principal Display Panel – Heparin Sodium Injection, USP 50,000 USP units per 10 mL Vial Label NDC 71288- 403 -10 Rx only Heparin Sodium Injection, USP 50,000 USP units per 10 mL (5,000 USP units per mL) NOT for Lock Flush For Intravenous or Subcutaneous Use 10 mL Multi-Dose Vial Principal Display Panel – Heparin Sodium Injection, USP 50,000 USP units per 10 mL Vial Label","Principal Display Panel – Heparin Sodium Injection, USP 50,000 USP units per 10 mL Carton NDC 71288- 403 -11 25 x 10 mL Multi-Dose Vials Rx Only Heparin Sodium Injection, USP 50,000 USP units per 10 mL (5,000 USP units per mL) NOT for Lock Flush For Intravenous or Subcutaneous Use From Porcine Intestinal Mucosa Principal Display Panel – Heparin Sodium Injection, USP 50,000 USP units per 10 mL Carton","Principal Display Panel – Heparin Sodium Injection, USP 10,000 USP units per mL Vial Label NDC 71288- 404 -01 Rx only Heparin Sodium Injection, USP 10,000 USP units per mL NOT for Lock Flush For Intravenous or Subcutaneous Use 1 mL Single-Dose Vial Principal Display Panel – Heparin Sodium Injection, USP 10,000 USP units per mL Vial Label","Principal Display Panel – Heparin Sodium Injection, USP 10,000 USP units per mL Carton NDC 71288- 404 -02 25 x 1 mL Single-Dose Vials Discard unused portion Rx Only Heparin Sodium Injection, USP 10,000 USP units per mL NOT for Lock Flush For Intravenous or Subcutaneous Use From Porcine Intestinal Mucosa Principal Display Panel – Heparin Sodium Injection, USP 10,000 USP units per mL Carton","Principal Display Panel – Heparin Sodium Injection, USP 40,000 USP units per 4 mL Vial Label NDC 71288- 404 -04 Rx only Heparin Sodium Injection, USP 40,000 USP units per 4 mL (10,000 USP units per mL) 4 mL Multi-Dose Vial NOT for Lock Flush For Intravenous or Subcutaneous Use From Porcine Intestinal Mucosa Principal Display Panel – Heparin Sodium Injection, USP 40,000 USP units per 4 mL Vial Label","Principal Display Panel – Heparin Sodium Injection, USP 40,000 USP units per 4 mL Carton NDC 71288- 404 -05 25 x 4 mL Multi-Dose Vials Rx Only Heparin Sodium Injection, USP 40,000 USP units per 4 mL (10,000 USP units per mL) NOT for Lock Flush For Intravenous or Subcutaneous Use From Porcine Intestinal Mucosa Principal Display Panel – Heparin Sodium Injection, USP 40,000 USP units per 4 mL Carton","Principal Display Panel – Heparin Sodium Injection, USP 1,000 USP units per mL MDV Vial Label NDC 71288- 449 -01 Rx Only Heparin Sodium Injection, USP 1,000 USP units per mL NOT for Lock Flush For Intravenous or Subcutaneous Use 1 mL Multi-Dose Vial Principal Display Panel – Heparin Sodium Injection, USP 1,000 USP units per mL MDV Vial Label","Principal Display Panel – Heparin Sodium Injection, USP 1,000 USP units per mL MDV Carton Label NDC 71288- 449 -02 25 x 1 mL Multi-Dose Vials Rx Only Heparin Sodium Injection, USP 1,000 USP units per mL NOT for Lock Flush For Intravenous or Subcutaneous Use From Porcine Intestinal Mucosa Principal Display Panel – Heparin Sodium Injection, USP 1,000 USP units per mL MDV Carton Label","Principal Display Panel – Heparin Sodium Injection, USP 5,000 USP units per mL MDV Vial Label NDC 71288- 450 -01 Rx Only Heparin Sodium Injection, USP 5,000 USP units per mL NOT for Lock Flush For Intravenous or Subcutaneous Use 1 mL Multi-Dose Vial Principal Display Panel – Heparin Sodium Injection, USP 5,000 USP units per mL MDV Vial Label","Principal Display Panel – Heparin Sodium Injection, USP 5,000 USP units per mL MDV Carton Label NDC 71288- 450 -02 25 x 1 mL Multi-Dose Vials Rx Only Heparin Sodium Injection, USP 5,000 USP units per mL NOT for Lock Flush For Intravenous or Subcutaneous Use From Porcine Intestinal Mucosa Principal Display Panel – Heparin Sodium Injection, USP 5,000 USP units per mL MDV Carton Label","Principal Display Panel – Heparin Sodium Injection, USP 10,000 USP units per mL MDV Vial Label NDC 71288- 451 -01 Rx Only Heparin Sodium Injection, USP 10,000 USP units per mL NOT for Lock Flush For Intravenous or Subcutaneous Use 1 mL Multi-Dose Vial Principal Display Panel – Heparin Sodium Injection, USP 10,000 USP units per mL MDV Vial Label","Principal Display Panel – Heparin Sodium Injection, USP 10,000 USP units per mL MDV Carton Label NDC 71288- 451 -02 25 x 1 mL Multi-Dose Vials Rx Only Heparin Sodium Injection, USP 10,000 USP units per mL NOT for Lock Flush For Intravenous or Subcutaneous Use From Porcine Intestinal Mucosa Principal Display Panel – Heparin Sodium Injection, USP 1,000 USP units per mL MDV Carton Label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term studies in animals have been performed to evaluate carcinogenic potential of heparin. Also, no reproduction studies in animals have been performed concerning mutagenesis or impairment of fertility."]},"tags":[{"label":"Anti-coagulant","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Antithrombin-III","category":"target"},{"label":"SERPINC1","category":"gene"},{"label":"B01AB01","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Infiltration","category":"route"},{"label":"Gel","category":"form"},{"label":"Injection","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Deep Vein Thrombosis with Pulmonary Embolism","category":"indication"},{"label":"Deep venous thrombosis","category":"indication"},{"label":"Disseminated intravascular coagulation","category":"indication"},{"label":"Maintain Patency of Indwelling Vascular Catheter","category":"indication"},{"label":"Non-Q wave myocardial infarction","category":"indication"},{"label":"Peripheral Arterial Thromboembolism Prevention","category":"indication"},{"label":"Organon Usa Inc","category":"company"},{"label":"Approved 1930s","category":"decade"},{"label":"Anticoagulants","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Fibrinolytic Agents","category":"pharmacology"},{"label":"Hematologic Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"HEPARIN-INDUCED THROMBOCYTOPENIA","source":"FDA FAERS","actionTaken":"1242 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"1189 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"719 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"705 reports"},{"date":"","signal":"DRUG HYPERSENSITIVITY","source":"FDA FAERS","actionTaken":"611 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"580 reports"},{"date":"","signal":"HYPOTENSION","source":"FDA FAERS","actionTaken":"557 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"528 reports"},{"date":"","signal":"PULMONARY EMBOLISM","source":"FDA FAERS","actionTaken":"475 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"471 reports"}],"drugInteractions":[{"url":"/drug/magnesium-salicylate","drug":"magnesium salicylate","action":"Monitor closely","effect":"May interact with Magnesium Salicylate","source":"DrugCentral","drugSlug":"magnesium-salicylate"},{"url":"/drug/salicylic-acid","drug":"salicylic acid","action":"Monitor closely","effect":"May interact with Sodium Salicylate","source":"DrugCentral","drugSlug":"salicylic-acid"},{"url":"/drug/salsalate","drug":"salsalate","action":"Monitor closely","effect":"May interact with Salsalate","source":"DrugCentral","drugSlug":"salsalate"},{"url":"/drug/thiosalicylic-acid","drug":"thiosalicylic acid","action":"Monitor closely","effect":"May interact with Sodium Thiosalicylate","source":"DrugCentral","drugSlug":"thiosalicylic-acid"}],"commonSideEffects":[{"effect":"Heparin-induced thrombocytopenia","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Vascular stent thrombosis","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Haemorrhage","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Haematoma","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Labelled drug-drug interaction medication error","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Premature baby","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Cardiogenic shock","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Multiple organ dysfunction syndrome","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Shock haemorrhagic","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Premature delivery","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Arthralgia","drugRate":"","severity":"common","_validated":false,"_confidence":0.3}],"contraindications":["Acute gastric ulcer with hemorrhage","Acute nephropathy","Antithrombin III deficiency","Arteriosclerosis obliterans","Bacterial endocarditis","Bleeding","Blood coagulation disorder","Cerebral hemorrhage","Diabetic retinopathy","Disease of blood AND/OR blood-forming organ","Disorder of biliary tract","Dissection of aorta","Diverticulitis of gastrointestinal tract","Gastrointestinal hemorrhage","Gastrointestinal ulcer","Hemophilia","Hemorrhagic cerebral infarction","Heparin-induced thrombocytopenia","Hepatic failure","Hypertensive retinopathy","Hypertensive urgency","Indwelling Vascular Catheter","Infective endocarditis","Intracranial hemorrhage","Local anesthetic intrathecal block"],"specialPopulations":{"Pregnancy":"There are no adequate and well-controlled studies on heparin use in pregnant women. In published reports, heparin exposure during pregnancy did not show evidence of an increased risk of adverse maternal or fetal outcomes in humans. Heparin sodium does not cross the placenta based on human and animal studies. Administration of heparin to pregnant animals at doses higher than the maximum human daily dose based on body weight resulted in increased resorptions. Use heparin sodium during pregnancy only if the potential benefits justify the potential risks to the fetus.","Geriatric use":"A higher incidence of bleeding has been reported in patients over 60 years of age, especially women. Clinical studies indicate that lower doses of heparin may be indicated in these patients.","Paediatric use":"There are no adequate and well-controlled studies on heparin use in pediatric patients. Pediatric dosing recommendations are based on clinical experience. Carefully examine all Heparin Sodium Injection vials to confirm choice of the correct strength prior to administration of the drug. Pediatric patients, including neonates, have died as result of medication errors in which HEPARIN SODIUM INJECTION vials have been confused with catheter lock solutions."}},"trials":[],"aliases":[],"company":"Merck & Co.","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$2.8055/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$1,010","description":"HEPARIN SODIUM 10,000 UNIT/ML VIAL","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=HEPARIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:40:03.429279+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:40:09.404831+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:40:02.537406+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=HEPARIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:40:09.994738+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:39:57.462150+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:39:57.462174+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:40:11.617554+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Antithrombin-III activator","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:40:11.184688+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4650299/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:40:10.844010+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA211007","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:39:57.462177+00:00"}},"allNames":"heparin sodium in plastic container","offLabel":[],"synonyms":["heparin","heparin sodium","heparin calcium"],"timeline":[{"date":"1939-02-09","type":"positive","source":"DrugCentral","milestone":"FDA approval (Organon Usa Inc)"}],"aiSummary":"Heparin Sodium In Plastic Container (HEPARIN) is an anti-coagulant medication originally developed by ORGANON USA INC and currently owned by the same company. It targets Antithrombin-III and is used to treat various conditions such as deep vein thrombosis, pulmonary embolism, and non-Q wave myocardial infarction. Heparin is a small molecule medication that has been FDA approved since 1939 and is off-patent, meaning it is available from generic manufacturers. It is used to prevent blood clot formation and maintain patency of indwelling vascular catheters. As an off-patent medication, it is widely available and used in clinical practice.","approvals":[{"date":"1939-02-09","orphan":false,"company":"ORGANON USA INC","regulator":"FDA"}],"brandName":"Heparin Sodium In Plastic Container","ecosystem":[{"indication":"Deep Vein Thrombosis with Pulmonary Embolism","otherDrugs":[{"name":"warfarin","slug":"warfarin","company":"Bristol Myers Squibb"}],"globalPrevalence":null},{"indication":"Deep venous thrombosis","otherDrugs":[{"name":"bemiparin","slug":"bemiparin","company":"Pfizer Inc"},{"name":"enoxaparin sodium","slug":"enoxaparin-sodium","company":"Sanofi Aventis Us"},{"name":"fondaparinux","slug":"fondaparinux","company":"Mylan Ireland Ltd"},{"name":"rivaroxaban","slug":"rivaroxaban","company":"Janssen Pharms"}],"globalPrevalence":null},{"indication":"Disseminated intravascular coagulation","otherDrugs":[],"globalPrevalence":null},{"indication":"Maintain Patency of Indwelling Vascular Catheter","otherDrugs":[],"globalPrevalence":null},{"indication":"Non-Q wave myocardial infarction","otherDrugs":[{"name":"clopidogrel","slug":"clopidogrel","company":"Sanofi Aventis Us"},{"name":"tirofiban","slug":"tirofiban","company":"Medicure"}],"globalPrevalence":null},{"indication":"Peripheral Arterial Thromboembolism Prevention","otherDrugs":[{"name":"clopidogrel","slug":"clopidogrel","company":"Sanofi Aventis Us"}],"globalPrevalence":null},{"indication":"Peripheral arterial embolism","otherDrugs":[],"globalPrevalence":null},{"indication":"Prevention of Cardiac Ischemia in Unstable Angina","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Antithrombin-III","novelty":"First-in-class","targets":[{"gene":"SERPINC1","source":"DrugCentral","target":"Antithrombin-III","protein":"Antithrombin-III"}],"modality":"Small Molecule","drugClass":"Anti-coagulant","explanation":"Heparin sodium interacts with the naturally occurring plasma protein, Antithrombin III, to induce conformational change, which markedly enhances the serine protease activity of Antithrombin III, thereby inhibiting the activated coagulation factors involved in the clotting sequence, particularly Xa and IIa. Small amounts of heparin sodium inhibit Factor Xa, and larger amounts inhibit thrombin (Factor IIa). Heparin sodium also prevents the formation of stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor. Heparin sodium does not have fibrinolytic activity; therefore, it will not lyse existing clots.","oneSentence":"Heparin works by binding to Antithrombin-III, a protein that inhibits the formation of blood clots.","technicalDetail":"Heparin exerts its anticoagulant effect by binding to Antithrombin-III, a serine protease inhibitor, which accelerates the inhibition of thrombin and other coagulation enzymes, thereby preventing the formation of blood clots.","_target_confidence":0.5},"commercial":{"launchDate":"1939","_launchSource":"DrugCentral (FDA 1939-02-09, ORGANON USA INC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1358","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=HEPARIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=HEPARIN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T11:52:36.555488","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:40:14.589886+00:00","fieldsConflicting":12,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"enoxaparin sodium","drugSlug":"enoxaparin-sodium","fdaApproval":"1993-03-29","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"bemiparin","drugSlug":"bemiparin","fdaApproval":"1994-12-22","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"heparin","indications":{"approved":[{"name":"Deep Vein Thrombosis with Pulmonary Embolism","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Patients undergoing major abdominothoracic surgery or at risk of developing thromboembolic disease"},{"name":"Deep venous thrombosis","source":"DrugCentral","snomedId":128053003,"regulator":"FDA","eligibility":"Patients undergoing major abdominothoracic surgery or at risk of developing thromboembolic disease"},{"name":"Disseminated intravascular coagulation","source":"DrugCentral","snomedId":67406007,"regulator":"FDA","eligibility":"Diagnosis and treatment of acute and chronic consumptive coagulopathies"},{"name":"Maintain Patency of Indwelling Vascular Catheter","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Not specified"},{"name":"Non-Q wave myocardial infarction","source":"DrugCentral","snomedId":314207007,"regulator":"FDA","eligibility":"Not specified"},{"name":"Peripheral Arterial Thromboembolism Prevention","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Not specified"},{"name":"Peripheral arterial embolism","source":"DrugCentral","snomedId":286959000,"regulator":"FDA","eligibility":"Prophylaxis and treatment of peripheral arterial embolism"},{"name":"Prevention of Cardiac Ischemia in Unstable Angina","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Not specified"},{"name":"Prevention of Ischemic Complications of Non-Q Wave MI","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Not specified"},{"name":"Prevention of Recurrent Venous Thrombosis Associated with Malignancy","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Not specified"},{"name":"Prevention of deep vein thrombosis","source":"DrugCentral","snomedId":439993001,"regulator":"FDA"},{"name":"Pulmonary Thromboembolism Prevention","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Pulmonary thromboembolism","source":"DrugCentral","snomedId":233935004,"regulator":"FDA"}],"offLabel":[{"name":"Acute coronary syndrome","source":"DrugCentral","drugName":"HEPARIN","evidenceCount":1475,"evidenceLevel":"strong"},{"name":"Coronavirus infection","source":"DrugCentral","drugName":"HEPARIN","evidenceCount":1542,"evidenceLevel":"strong"},{"name":"Myocardial infarction","source":"DrugCentral","drugName":"HEPARIN","evidenceCount":6251,"evidenceLevel":"strong"},{"name":"Percutaneous coronary intervention","source":"DrugCentral","drugName":"HEPARIN","evidenceCount":3004,"evidenceLevel":"strong"}],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"enoxaparin-sodium","brandName":"enoxaparin sodium","genericName":"enoxaparin sodium","approvalYear":"1993","relationship":"same-class"},{"drugId":"bemiparin","brandName":"bemiparin","genericName":"bemiparin","approvalYear":"1994","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07494877","phase":"","title":"Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2025-09-01","conditions":["Infertility"],"enrollment":300,"completionDate":"2027-12-31"},{"nctId":"NCT04790370","phase":"PHASE4","title":"Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Scientific Corporation","startDate":"2021-08-02","conditions":["Pulmonary Embolism"],"enrollment":544,"completionDate":"2026-08"},{"nctId":"NCT07497165","phase":"","title":"Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-11-01","conditions":["Relapsed/Refractory Multiple Myeloma (RRMM)","Multiple Myeloma"],"enrollment":48,"completionDate":"2027-06-30"},{"nctId":"NCT04994977","phase":"PHASE1","title":"Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2023-05-04","conditions":["Atypical Choroid Plexus Papilloma","Choroid Plexus Carcinoma"],"enrollment":1,"completionDate":"2025-12-01"},{"nctId":"NCT07492901","phase":"NA","title":"Impact of Ligament of Marshall Resection on Atrial Fibrillation Occurrence in Patients Undergoing Coronary Artery Bypass Grafting: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2024-01-11","conditions":["Post Operative Arrythmia"],"enrollment":220,"completionDate":"2025-11-30"},{"nctId":"NCT07491731","phase":"","title":"Zeus (510K) - 24024 - Stability in Venous and Arterial Blood","status":"TERMINATED","sponsor":"Radiometer Medical ApS","startDate":"2025-10-07","conditions":["Critical Care, Intensive Care"],"enrollment":43,"completionDate":"2026-01-09"},{"nctId":"NCT02870738","phase":"PHASE2","title":"Bladder Directed vs. Pelvic Floor Therapy in IC/BPS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Corewell Health East","startDate":"2017-04-21","conditions":["Cystitis, Interstitial","Painful Bladder Syndrome"],"enrollment":128,"completionDate":"2026-08"},{"nctId":"NCT07162064","phase":"PHASE3","title":"Heparin for RAO Post-Transradial Angiography in AIS","status":"COMPLETED","sponsor":"Xiang Luo","startDate":"2025-08-04","conditions":["Acute Ischemic Stroke"],"enrollment":440,"completionDate":"2026-02-04"},{"nctId":"NCT06753786","phase":"NA","title":"Timing of Venous Thromboembolism Prophylaxis in Patients With Hypertensive Intracerebral Hemorrhage","status":"RECRUITING","sponsor":"Pirogov Russian National Research Medical University","startDate":"2024-10-21","conditions":["Venous Thromboembolism","Pulmonary Embolism","Intracerebral Hemorrhage","Deep Vein Thrombosis"],"enrollment":200,"completionDate":"2028-12-31"},{"nctId":"NCT07491393","phase":"PHASE4","title":"Pharmacokinetic Study of the Use of Nefopam 30 mg Tablets in Patients Suffering From Acute Pain in Rheumatology","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2026-04-01","conditions":["Acute Rheumatic Pain"],"enrollment":24,"completionDate":"2027-04-07"},{"nctId":"NCT06096064","phase":"","title":"Medication Use Evaluation (MUE) for Continuous Heparin Infusions in Hospitalized Patients","status":"COMPLETED","sponsor":"Methodist Health System","startDate":"2022-10-31","conditions":["Unfractionated Heparin"],"enrollment":100,"completionDate":"2023-08-21"},{"nctId":"NCT07461545","phase":"NA","title":"Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS","status":"RECRUITING","sponsor":"Northern Jiangsu People's Hospital","startDate":"2026-02-04","conditions":["Cirrhosis","Splenectomy","Venous Thrombosis","Hypertension, Portal"],"enrollment":40,"completionDate":"2027-03-01"},{"nctId":"NCT05597488","phase":"NA","title":"EUS Guided Portal-systemic Pressure Gradient Measurement to Predict Treatment Response and Outcomes of Varices to Endoscopic Variceal Ligation in Patients With Chronic Hepatitis.","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2022-11-01","conditions":["Cirrhosis Portal"],"enrollment":160,"completionDate":"2026-10-31"},{"nctId":"NCT04633356","phase":"PHASE1,PHASE2","title":"EUS Guided Portal-systemic Pressure Gradient Measurement","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2020-11-12","conditions":["Portal Hypertension","Cirrhosis"],"enrollment":30,"completionDate":"2026-11-11"},{"nctId":"NCT06667999","phase":"PHASE4","title":"The Intensive Care Platform Trial","status":"RECRUITING","sponsor":"Anders Perner","startDate":"2025-06-26","conditions":["Intensive Care Patients","Intensive Care Unit Patients","Critical Illness"],"enrollment":10000,"completionDate":"2035-12"},{"nctId":"NCT07145437","phase":"NA","title":"Prostate Stereotactic Radiation and Radio-induced Lymphocyte Apoptosis for Predicting Late Toxicities in Prostate Cancer (PROSTERA)","status":"NOT_YET_RECRUITING","sponsor":"Clinique Sainte Clotilde","startDate":"2026-04-01","conditions":["Prostate Cancer"],"enrollment":220,"completionDate":"2030-11-01"},{"nctId":"NCT05900388","phase":"","title":"A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)","status":"NOT_YET_RECRUITING","sponsor":"Bayer","startDate":"2026-09-01","conditions":["Venous Thromboembolism","Children Under 2 Years"],"enrollment":850,"completionDate":"2029-06-30"},{"nctId":"NCT07477977","phase":"NA","title":"Dose for Reversal of Heparin After Cardiopulmonary Bypass","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2026-03-01","conditions":["Open Heart Surgery"],"enrollment":195,"completionDate":"2026-09-01"},{"nctId":"NCT07467889","phase":"","title":"Impact of CRRT on Serum Carnitine and Micronutrient Levels","status":"COMPLETED","sponsor":"Gulhane Training and Research Hospital","startDate":"2023-01-01","conditions":["Acute Kidney Injury (Nontraumatic)","Critical Illness"],"enrollment":43,"completionDate":"2025-12-15"},{"nctId":"NCT07299695","phase":"PHASE3","title":"Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Argyrios Tzouvelekis","startDate":"2026-01-25","conditions":["Idiopathic Pulmonary Fibrosis","Acute Exacerbation of Idiopathic Pulmonary Fibrosis"],"enrollment":196,"completionDate":"2028-12"},{"nctId":"NCT02675647","phase":"PHASE4","title":"Heparin Based on Ideal Body Weight for Cardiopulmonary Bypass in Obese Patients","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2015-12","conditions":["Cardiac Surgery","Cardiopulmonary Bypass","Obese Patients (BMI ≥ 30 kg/m²)"],"enrollment":60,"completionDate":"2017-12"},{"nctId":"NCT02860299","phase":"PHASE4","title":"Biological and Clinical Measurements Following Systemic Leakage When a Citrate or Heparin Lock is Used","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2015-02","conditions":["Acute Renal Insufficiency"],"enrollment":76,"completionDate":""},{"nctId":"NCT04618913","phase":"","title":"Anticoagulation in Patients With Venous Thromboembolism and Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-12-14","conditions":["Neoplasms","Embolism"],"enrollment":1,"completionDate":"2026-04-06"},{"nctId":"NCT07464808","phase":"NA","title":"Utilizing Anti-Factor Xa as a Predictive Tool for Optimizing Outcome in Burn Patients' Management","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2025-11-28","conditions":["Venous Thromboembolic Event"],"enrollment":25,"completionDate":"2027-11-30"},{"nctId":"NCT07434908","phase":"","title":"Heparin-binding Protein and Lungedema in ICU Patients.","status":"RECRUITING","sponsor":"Umeå University","startDate":"2024-05-06","conditions":["Lung Edema"],"enrollment":25,"completionDate":"2026-07-01"},{"nctId":"NCT07462182","phase":"NA","title":"Impact of Enoxaparin Therapy on Fetal Outcomes in Intrauterine Growth Restriction","status":"NOT_YET_RECRUITING","sponsor":"Muhammad Aamir Latif","startDate":"2026-04-01","conditions":["Intrauterine Growth Restriction"],"enrollment":108,"completionDate":"2026-09-30"},{"nctId":"NCT05758480","phase":"NA","title":"Characterization of the Immunometabolic Signature in Long COVID-19.","status":"COMPLETED","sponsor":"University Hospital, Angers","startDate":"2023-05-24","conditions":["Long COVID"],"enrollment":62,"completionDate":"2025-11-03"},{"nctId":"NCT07015905","phase":"PHASE3","title":"REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-06-25","conditions":["Venous Thromboembolism (VTE)"],"enrollment":2000,"completionDate":"2027-05-12"},{"nctId":"NCT03297281","phase":"NA","title":"Stop or Ongoing Oral Anticoagulation in Patients Undergoing Pvp (SOAP)","status":"RECRUITING","sponsor":"Clinique Pasteur","startDate":"2017-10-30","conditions":["Benign Prostatic Hyperplasia","Anticoagulant Adverse Reaction"],"enrollment":389,"completionDate":"2028-05-31"},{"nctId":"NCT07454434","phase":"NA","title":"The Effect of Music on Anxiety Levels and Sleep Quality in Patients Who Have a Myocardial Infarction","status":"NOT_YET_RECRUITING","sponsor":"Mersin University","startDate":"2026-02-23","conditions":["Sleep Quality","Anxiety"],"enrollment":64,"completionDate":"2026-08-30"},{"nctId":"NCT05540340","phase":"PHASE1","title":"A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-09-09","conditions":["Lymphoma","Lymphoma, B-Cell","Lymphoma, T-Cell","Lymphoma, Hodgkin","Lymphoma, Non-Hodgkin"],"enrollment":39,"completionDate":"2027-09"},{"nctId":"NCT03187743","phase":"NA","title":"Personalised Pharmacological Approach to the Tapering of Corticosteroid Doses in Systemic Lupus Patients Treated With Prednisone","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-04-17","conditions":["Lupus Erythematosus, Systemic"],"enrollment":72,"completionDate":"2022-04-20"},{"nctId":"NCT06549842","phase":"NA","title":"Safe and Fast Radial Hemostasis Using Synergistic Strategies: SAFE & FAST Trial","status":"COMPLETED","sponsor":"Regional Hospital of Scranton","startDate":"2024-08-15","conditions":["Cardiovascular Diseases","Bleeding","Arterial Puncture","Catheter Complications","Occlusion of Artery"],"enrollment":451,"completionDate":"2026-02-20"},{"nctId":"NCT06055920","phase":"NA","title":"The PEERLESS II Study","status":"RECRUITING","sponsor":"Inari Medical","startDate":"2023-11-17","conditions":["Pulmonary Embolism"],"enrollment":1200,"completionDate":"2026-07"},{"nctId":"NCT01874769","phase":"","title":"Study of Immune Tolerance and Capacity for Wound Healing of Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2013-08","conditions":["Recessive Dystrophic Epidermolysis Bullosa"],"enrollment":30,"completionDate":"2017-08"},{"nctId":"NCT02653092","phase":"NA","title":"Reprometabolic Syndrome Mediates Subfertility in Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2016-06","conditions":["Obesity","Infertility","Hypogonadotropic Hypogonadotropism","Hyperinsulinemia"],"enrollment":84,"completionDate":"2026-12-11"},{"nctId":"NCT06454630","phase":"PHASE2","title":"A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-06-27","conditions":["Venous Thromboembolism"],"enrollment":179,"completionDate":"2025-01-21"},{"nctId":"NCT03041805","phase":"","title":"Caprini Score in Venous Surgery: a Prospective Cohort Study","status":"RECRUITING","sponsor":"Pirogov Russian National Research Medical University","startDate":"2017-01-01","conditions":["Venous Thromboembolism","Varicose Veins"],"enrollment":3000,"completionDate":"2027-01-01"},{"nctId":"NCT07288489","phase":"PHASE3","title":"Phase 3 Trial of VMX-C001 vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.","status":"NOT_YET_RECRUITING","sponsor":"VarmX B.V.","startDate":"2026-03","conditions":["Blood Loss, Surgical","Coagulation Disorder"],"enrollment":800,"completionDate":"2031-01"},{"nctId":"NCT03728166","phase":"NA","title":"Computerized Decision Support for Prevention of VTE in Hospitalized Medical Patients Across the Continuum of Care (DC-eALERT)","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2019-02-01","conditions":["Venous Thromboembolism"],"enrollment":400,"completionDate":"2026-06-30"},{"nctId":"NCT05286814","phase":"PHASE2","title":"PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-10-24","conditions":["Metastatic Colorectal Cancer (Mcrc)","Intrahepatic Cholangiocarcinoma (Icc)","Intrahepatic Bile Duct Cancer","Colorectal Neoplasms","Colorectal Cancer","Cholangiocarcinoma","Bile Duct Neoplasms","Bile Duct Cancer","Adrenocortical Carcinoma (ACC)","Adrenal Cortical Carcinoma","Adrenal Gland Cancer","Adrenal Gland Neoplasms","Adrenal Cortex Neoplasms"],"enrollment":70,"completionDate":"2028-12-31"},{"nctId":"NCT07312851","phase":"PHASE1","title":"A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-01-19","conditions":["Healthy Participants"],"enrollment":186,"completionDate":"2026-06-19"},{"nctId":"NCT05531474","phase":"NA","title":"Bariatric Surgery for the Reduction of cArdioVascular Events Randomized Controlled Trial","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2020-11-02","conditions":["Cardiovascular Complication","Bariatric Surgery Candidate"],"enrollment":200,"completionDate":"2027-07-01"},{"nctId":"NCT04374799","phase":"PHASE3","title":"Heparin vs Placebo for Cardiac Catheterization","status":"RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2020-10-05","conditions":["Cardiac Disease"],"enrollment":1623,"completionDate":"2026-12"},{"nctId":"NCT06679829","phase":"PHASE2","title":"A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-11-06","conditions":["Multiple Myeloma"],"enrollment":215,"completionDate":"2027-11"},{"nctId":"NCT07326215","phase":"NA","title":"A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+","status":"RECRUITING","sponsor":"Vantive Health LLC","startDate":"2025-12-11","conditions":["Acute Respiratory Distress Syndrome","Acute Kidney Injury"],"enrollment":99,"completionDate":"2026-08-31"},{"nctId":"NCT06604026","phase":"NA","title":"Investigational Study With the BD PosiFlush™ SafeScrub on NADs","status":"RECRUITING","sponsor":"Becton, Dickinson and Company","startDate":"2024-10-22","conditions":["CRBSI - Catheter Related Bloodstream Infection"],"enrollment":220,"completionDate":"2026-02-28"},{"nctId":"NCT07140211","phase":"PHASE3","title":"Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis","status":"RECRUITING","sponsor":"Marc Blondon","startDate":"2025-10-15","conditions":["Venous Thromboembolism (VTE)","Postpartum"],"enrollment":9200,"completionDate":"2030-08"},{"nctId":"NCT07404345","phase":"PHASE4","title":"Low-Dose Apixaban Added to Standard Heparin Lock Versus Heparin Lock Alone to Prevent Tunneled Hemodialysis Catheters Dysfunction (APICATH-HD)","status":"NOT_YET_RECRUITING","sponsor":"Hospital Civil de Guadalajara","startDate":"2026-03-01","conditions":["Hemodialysis Access Failure","Kidney Disease, End-Stage","Hemodialysis Catheter"],"enrollment":54,"completionDate":"2028-09-01"},{"nctId":"NCT06094920","phase":"PHASE4","title":"Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2024-07-29","conditions":["Diabetes Mellitus Type 2 With Proteinuria","Diabetes Mellitus, Type 2","Diabetes Mellitus","Diabetes","Diabetes Complications","Albuminuria","Chronic Kidney Diseases","Chronic Kidney Disease Due to Type 2 Diabetes Mellitus","Chronic Kidney Disease stage3","Chronic Kidney Disease stage4","CKD","CKD Stage 3","CKD Stage 4"],"enrollment":12,"completionDate":"2025-09-24"},{"nctId":"NCT05498428","phase":"PHASE2","title":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-11-11","conditions":["Carcinoma, Non-small-Cell Lung"],"enrollment":520,"completionDate":"2028-08-18"},{"nctId":"NCT06939088","phase":"PHASE2","title":"Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder","status":"RECRUITING","sponsor":"Anders Fink-Jensen, MD, DMSci","startDate":"2025-05-05","conditions":["Alcohol Use Disorder","Alcohol Abuse/Dependence","Alcohol Dependence","Alcoholism","Schizophrenia Disorders","Schizophrenia and Disorders With Psychotic Features","Schizophrenia and Schizophrenia Spectrum Psychosis","Schizophrenia"],"enrollment":108,"completionDate":"2028-12-31"},{"nctId":"NCT05707442","phase":"PHASE3","title":"Stent Implantation Versus Medical Therapy for Idiopathic IntracraniaL Hypertension (SIMPLE)","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2023-02-16","conditions":["Idiopathic Intracranial Hypotension","Venous Sinus Stenosis"],"enrollment":74,"completionDate":"2027-03"},{"nctId":"NCT04227678","phase":"NA","title":"Postprandial Fatty Acid Metabolism in Subjects With Lipoprotein Lipase Deficiency","status":"RECRUITING","sponsor":"Université de Sherbrooke","startDate":"2019-12-09","conditions":["Lipoprotein Lipase Deficiency"],"enrollment":16,"completionDate":"2027-03-30"},{"nctId":"NCT01652209","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of Hearticelgram®-AMI in Patients With Acute Myocardial Infarction.","status":"COMPLETED","sponsor":"Pharmicell Co., Ltd.","startDate":"2013-09-01","conditions":["Acute Myocardial Infarction"],"enrollment":90,"completionDate":"2024-08-12"},{"nctId":"NCT05890781","phase":"NA","title":"Engineering Immune Organoids to Study Pediatric Cancer","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2023-05-12","conditions":["Brain Tumor","Kidney Tumor","Neuroblastoma","Sarcoma"],"enrollment":108,"completionDate":"2028-05"},{"nctId":"NCT01962116","phase":"PHASE3","title":"Citrate Versus Heparin for the Lock of Non-tunneled Hemodialysis Catheters in Patients Hospitalised in ICU","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2013-06-14","conditions":["Patients With Acute Renal Insufficiency"],"enrollment":405,"completionDate":"2016-12-31"},{"nctId":"NCT07136714","phase":"PHASE4","title":"Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity","status":"RECRUITING","sponsor":"Nordsjaellands Hospital","startDate":"2025-09-11","conditions":["Major Depressive Disorder"],"enrollment":116,"completionDate":"2027-09"},{"nctId":"NCT07388420","phase":"NA","title":"Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis","status":"RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2026-01-02","conditions":["Hypertriglyceridemia Induced Acute Pancreatitis"],"enrollment":40,"completionDate":"2026-12-31"},{"nctId":"NCT07388927","phase":"PHASE4","title":"A Real-World Study on Effect of Hirudoid on Ecchymosis After Treatment of Crow's Feet With Botulinum Toxin Type A","status":"NOT_YET_RECRUITING","sponsor":"DKSH Management (Thailand) Limited","startDate":"2026-02","conditions":["Ecchymosis After Periorbital Rejuvenation With Botulinum Toxin Type A","Crow's Feet Lines","Lateral Canthal Lines, LCL"],"enrollment":48,"completionDate":"2026-04"},{"nctId":"NCT05306899","phase":"PHASE3","title":"Multi-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2022-06-01","conditions":["Chronic Daily Headache"],"enrollment":56,"completionDate":"2026-06-01"},{"nctId":"NCT07201519","phase":"PHASE2","title":"Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy","status":"RECRUITING","sponsor":"Michael J Cavnar, MD","startDate":"2026-01-23","conditions":["Colorectal Cancer Metastatic","Intrahepatic Cholangiocarcinoma"],"enrollment":80,"completionDate":"2030-02"},{"nctId":"NCT05701917","phase":"NA","title":"DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis","status":"RECRUITING","sponsor":"Inari Medical","startDate":"2023-01-06","conditions":["Venous Thromboembolism","Deep Venous Thrombosis","Post-Thrombotic Syndrome"],"enrollment":300,"completionDate":"2027-01-15"},{"nctId":"NCT07388056","phase":"","title":"Efficacy and Safety of Extended Anticoagulant Therapy in Cancer Associated Thrombosis in Thai Population","status":"COMPLETED","sponsor":"Thammasat University","startDate":"2012-01-01","conditions":["Cancer-associated Thrombosis"],"enrollment":169,"completionDate":"2025-12-31"},{"nctId":"NCT05848713","phase":"PHASE3","title":"AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia","status":"RECRUITING","sponsor":"University of Manitoba","startDate":"2023-10-10","conditions":["Community-acquired Pneumonia"],"enrollment":4000,"completionDate":"2029-03-31"},{"nctId":"NCT07352800","phase":"PHASE2","title":"Safety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia","status":"RECRUITING","sponsor":"Aplagon Oy","startDate":"2026-01-29","conditions":["Peripheral Arterial Occlusive Disease","Chronic Limb-Threatening Ischemia"],"enrollment":42,"completionDate":"2027-06-30"},{"nctId":"NCT07383155","phase":"PHASE4","title":"Bivalirudin Versus Heparin During PCI in High Bleeding Risk Patients With Acute Coronary Syndromes","status":"NOT_YET_RECRUITING","sponsor":"Shenyang Northern Hospital","startDate":"2026-02-01","conditions":["Percutaneous Coronary Intervention","High Bleeding Risk","Acute Coronary Syndromes","Anticoagulant Therapy"],"enrollment":5270,"completionDate":"2028-12-31"},{"nctId":"NCT02591199","phase":"PHASE2","title":"Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome","status":"TERMINATED","sponsor":"Urigen","startDate":"2015-09","conditions":["Interstitial Cystitis","Bladder Pain Syndrome"],"enrollment":91,"completionDate":"2018-06-18"},{"nctId":"NCT06313203","phase":"PHASE2","title":"HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT)","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2024-02-13","conditions":["Intrahepatic Cholangiocarcinoma","Chemotherapy Effect"],"enrollment":39,"completionDate":"2034-01"},{"nctId":"NCT06096116","phase":"PHASE3","title":"Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass","status":"RECRUITING","sponsor":"Octapharma","startDate":"2024-08-21","conditions":["Acquired Antithrombin Deficiency"],"enrollment":120,"completionDate":"2028-03"},{"nctId":"NCT06899776","phase":"","title":"Assessing Chest Pain Using Point-of-Care High-Sensitivity Troponin I in the Emergency Department","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2025-02-07","conditions":["ACS (Acute Coronary Syndrome)"],"enrollment":600,"completionDate":"2026-07"},{"nctId":"NCT04496362","phase":"PHASE4","title":"Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO) Heparin Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor Research Institute","startDate":"2018-10-10","conditions":["ECMO","Heparin","Respiratory Failure"],"enrollment":100,"completionDate":"2026-06"},{"nctId":"NCT07374978","phase":"NA","title":"Effect of Thrombolysis on 30-day Mortality in Intermediate High Risk Pulmonary Patients With Low Bleeding Risk","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-07-01","conditions":["Pulmonary Embolism Subacute Massive","Thrombolytic Therapy"],"enrollment":100,"completionDate":"2025-07-01"},{"nctId":"NCT06080074","phase":"PHASE2","title":"Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System","status":"RECRUITING","sponsor":"Stanford University","startDate":"2025-04-15","conditions":["Heart Failure","Cardiogenic Shock","Congenital Heart Disease","Cardiomyopathies"],"enrollment":50,"completionDate":"2029-09"},{"nctId":"NCT06243510","phase":"NA","title":"Comparison of Apixaban Versus Enoxaparin","status":"ENROLLING_BY_INVITATION","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2023-11-24","conditions":["Bladder Cancer"],"enrollment":90,"completionDate":"2026-06"},{"nctId":"NCT06381661","phase":"PHASE2","title":"Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-05-01","conditions":["Sepsis"],"enrollment":2000,"completionDate":"2031-05-01"},{"nctId":"NCT07366372","phase":"NA","title":"Efficacy of Taurolidine Containing Lock Solution for Prevention of Central Venous Catheter Infection in ICU Patients","status":"COMPLETED","sponsor":"Tanta University","startDate":"2023-05-01","conditions":["Taurolidine","Lock Solution","Prevention","Central Venous Catheter Infection","Intensive Care Unit"],"enrollment":120,"completionDate":"2024-11-01"},{"nctId":"NCT07365670","phase":"NA","title":"Comparison of the Best Method for Measuring Anti-Xa Activity in Children Receiving Unfractionated Heparin in Cardiac Intensive Care (COMPAXE-HNF)","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de la Réunion","startDate":"2026-04-01","conditions":["Congenital Heart Disease","Unfractionated Heparin","Anti Xa Activity"],"enrollment":22,"completionDate":"2029-04-05"},{"nctId":"NCT07365644","phase":"","title":"Prophylactic ANTicoagulation With HEparine in Critically Ill Patients With Renal Impairment","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier le Mans","startDate":"2026-01-01","conditions":["Prophylactic Anticoagulation"],"enrollment":1111,"completionDate":"2028-02-01"},{"nctId":"NCT06981624","phase":"NA","title":"Comparison of the Systematic Versus the Selective Use of Heparin for the Prevention of Radial Artery Occlusion","status":"RECRUITING","sponsor":"Olivier F. Bertrand","startDate":"2025-05-13","conditions":["Radial Artery Occlusion"],"enrollment":500,"completionDate":"2026-12"},{"nctId":"NCT07361783","phase":"NA","title":"Impact of Pre-Hospital Heparin Loading in STEMI Patients for Primary PCI: The HELP-PCI 2 Trial","status":"RECRUITING","sponsor":"Chen Jing","startDate":"2025-08-13","conditions":["Primary PCI","ST-elevation Myocardial Infarction (STEMI)"],"enrollment":6294,"completionDate":"2030-04-01"},{"nctId":"NCT07361679","phase":"PHASE4","title":"LDA and LMWH vs LDA Alone in High-risk Patients for Preeclampsia Prevention","status":"RECRUITING","sponsor":"Alexandra Hospital, Athens, Greece","startDate":"2023-01-18","conditions":["Preeclampsia Severe","Toxemia Of Pregnancy","Preeclampsia","Pregnancy Complications","Hypertension, Pregnancy-Induced","Gestational Hypertension"],"enrollment":100,"completionDate":"2027-07-01"},{"nctId":"NCT06394830","phase":"PHASE2","title":"Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)","status":"RECRUITING","sponsor":"Vaneltix Pharma, Inc.","startDate":"2024-12-13","conditions":["Interstitial Cystitis","Bladder Pain Syndrome"],"enrollment":50,"completionDate":"2026-06"},{"nctId":"NCT05737121","phase":"PHASE2","title":"Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS","status":"RECRUITING","sponsor":"Vaneltix Pharma, Inc.","startDate":"2023-05-22","conditions":["Interstitial Cystitis","Bladder Pain Syndrome"],"enrollment":120,"completionDate":"2026-06"},{"nctId":"NCT07361081","phase":"","title":"Protocol-Driven Continuous Infusion Versus Intermittent Bolus Heparin During Atrial Fibrillation Ablation","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2022-09-01","conditions":["Atrial Fibrillation (AF)","Ablation"],"enrollment":300,"completionDate":"2028-12-31"},{"nctId":"NCT06315530","phase":"PHASE2","title":"Effect of Telitacicept on Antibody Titers in Primary APS Patients","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2023-12-01","conditions":["Antiphospholipid Syndrome (APS)"],"enrollment":20,"completionDate":"2026-01-06"},{"nctId":"NCT07352358","phase":"PHASE4","title":"Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous Thrombosis","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2026-01-30","conditions":["Cerebral Venous Thrombosis"],"enrollment":72,"completionDate":"2028-07-01"},{"nctId":"NCT04273607","phase":"PHASE2,PHASE3","title":"Anticoagulation-free VV ECMO for Acute Respiratory Failure","status":"RECRUITING","sponsor":"Damian Ratano","startDate":"2022-09-01","conditions":["Extracorporeal Membrane Oxygenation Complication"],"enrollment":40,"completionDate":"2027-01-30"},{"nctId":"NCT07124819","phase":"PHASE3","title":"Dimolegin® (60 mg) Given Once Daily in Patients Undergoing Total Hip or Knee Replacement Compared to Enoxaparin","status":"COMPLETED","sponsor":"Avexima Diol LLC","startDate":"2024-07-22","conditions":["Arthroplasty, Replacement, Hip","Arthroplasty, Replacement, Knee","Venous Thromboembolism (VTE)","Prevention"],"enrollment":215,"completionDate":"2025-01-14"},{"nctId":"NCT04268940","phase":"","title":"Thrombo-Elastography Guided Management of ECMO","status":"COMPLETED","sponsor":"Damian Ratano","startDate":"2020-06-03","conditions":["Extracorporeal Circulation of Blood; Thrombocytopenia"],"enrollment":61,"completionDate":"2021-06-04"},{"nctId":"NCT06781294","phase":"NA","title":"SIRAKI 02 Posthoc Analysis.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospital Universitari de Bellvitge","startDate":"2024-10-01","conditions":["Cardiac Surgery Requiring Cardiopulmonary Bypass","Acute Kidney Injury","Chronic Kidney Disease(CKD)","Kidney Failure, Acute"],"enrollment":343,"completionDate":"2027-03-01"},{"nctId":"NCT07140523","phase":"PHASE2","title":"A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA","status":"RECRUITING","sponsor":"Sirius Therapeutics Co., Ltd.","startDate":"2025-09-16","conditions":["Venous Thromboembolism"],"enrollment":450,"completionDate":"2026-10-31"},{"nctId":"NCT07342127","phase":"","title":"Evaluation of a Preventive Therapeutic Strategy for Postpartum Venous Thromboembolism in Women With Genetic Risk Factor","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2026-02-01","conditions":["Factor V Leiden Heterozygous Mutation","Factor II Heterozygous Mutation","Pregnancy","Postpartum"],"enrollment":100,"completionDate":"2026-08-01"},{"nctId":"NCT07330661","phase":"NA","title":"Nursing-Led Deep Vein Thrombosis Prevention in Neurosurgery","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2021-01-01","conditions":["Deep Vein Thrombosis (DVT)"],"enrollment":1286,"completionDate":"2024-05-01"},{"nctId":"NCT05459818","phase":"","title":"Individual Patient Data Analysis of Viabahn for Peripheral Arterial Disease","status":"COMPLETED","sponsor":"Rijnstate Hospital","startDate":"2022-10-12","conditions":["Peripheral Vascular Diseases"],"enrollment":977,"completionDate":"2025-10-01"},{"nctId":"NCT06937372","phase":"NA","title":"Delivery and Implementation of a Randomised Crossover Trial on Thrombosis","status":"NOT_YET_RECRUITING","sponsor":"Queen Mary University of London","startDate":"2026-08-01","conditions":["Hip Fractures","Venous Thromboembolism (VTE)"],"enrollment":21194,"completionDate":"2028-04-30"},{"nctId":"NCT00508924","phase":"PHASE2","title":"Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2005-08","conditions":["Coronary Artery Disease","Angina, Unstable"],"enrollment":140,"completionDate":"2006-10"},{"nctId":"NCT00861692","phase":"PHASE2","title":"Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-04","conditions":["Heparin-induced Thrombocytopenia Type II"],"enrollment":20,"completionDate":"2011-02"},{"nctId":"NCT07270263","phase":"NA","title":"Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies","status":"RECRUITING","sponsor":"Medical University of Gdansk","startDate":"2024-11-22","conditions":["Lymphoma","Leukemia","Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma","Venous Thromboembolic Disease","VTE (Venous Thromboembolism)","PE - Pulmonary Embolism","Hematologic Malignacies"],"enrollment":100,"completionDate":"2026-12-31"},{"nctId":"NCT06822426","phase":"PHASE3","title":"Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)","status":"RECRUITING","sponsor":"CorMedix","startDate":"2025-05-14","conditions":["Central Line Associated Blood Stream Infections (CLABSI)"],"enrollment":200,"completionDate":"2027-01"}],"whoEssential":true,"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Gel, Injection","formulations":[{"form":"GEL","route":"INFILTRATION","productName":"ICEKING Skin Expert Heparin Scar Repair Gel"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"HEPARIN SODIUM"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"Heparin Sodium"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"Heparin Sodium"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"Heparin Sodium in Dextrose"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"Heparin Sodium in Sodium Chloride"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"HEPARIN SODIUM"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Heparin Sodium"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Heparin sodium"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"HEPARIN SODIUM"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"HEPARIN SODIUM IN SODIUM CHLORIDE"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Heparin Sodium"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Heparin Sodium and Dextrose"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Heparin Sodium"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Heparin Sodium"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"32703","NDDF":"002079","UNII":"T2410KM04A","CHEBI":"CHEBI:28304","VANDF":"4017546","INN_ID":"392","RXNORM":"20044","UMLSCUI":"C0019134","chemblId":"CHEMBL4650299","ChEMBL_ID":"CHEMBL1909300","KEGG_DRUG":"D02112","DRUGBANK_ID":"DB01109","PDB_CHEM_ID":"M7J","PUBCHEM_CID":"92044406","SNOMEDCT_US":"29725000","IUPHAR_LIGAND_ID":"4214","SECONDARY_CAS_RN":"37270-89-6","MESH_DESCRIPTOR_UI":"D006493"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1939-","companyName":"Organon Usa Inc","relationship":"Original Developer"}],"publicationCount":91181,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"B01AB01","allCodes":["B01AB01","B01AB51","C05BA03","C05BA53","S01XA14"]},"biosimilarFilings":[],"originalDeveloper":"Organon Usa Inc","recentPublications":[],"combinationProducts":[{"brandName":"Heparin Sodium in Dextrose","ingredients":"glucose + heparin"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Merck & Co.","companyId":"merck","modality":"Oligosaccharide","firstApprovalDate":"1939","enrichmentLevel":4,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1939-02-09T00:00:00.000Z","mah":"ORGANON USA INC","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1939-02-09T00:00:00.000Z","mah":"ORGANON USA INC","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1939-02-09T00:00:00.000Z","mah":"ORGANON USA INC","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1939-02-09T00:00:00.000Z","mah":"ORGANON USA INC","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1939-02-09T00:00:00.000Z","mah":"ORGANON USA INC","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1939-02-09T00:00:00.000Z","mah":"ORGANON USA INC","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1993-12-01T00:00:00.000Z","mah":"HOSPIRA","brand_name_local":null,"application_number":"ANDA088100"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2016-06-10T00:00:00.000Z","mah":"FRESENIUS KABI USA","brand_name_local":null,"application_number":"ANDA206552"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2016-07-18T00:00:00.000Z","mah":"HOSPIRA","brand_name_local":null,"application_number":"NDA018916"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-02-06T00:00:00.000Z","mah":"GLAND","brand_name_local":null,"application_number":"ANDA205323"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-12-19T00:00:00.000Z","mah":"CORMEDIX","brand_name_local":null,"application_number":"NDA214520"},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"Un","currency":"USD","price_amount":"1010.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:40:14.589886+00:00","fieldsConflicting":12,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}